Advisor Group’s GenMark Diagnostics, Inc GNMK Stock Holding History

Advisor Group’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$21K	Buy	4,264 +1,302	+44%	+$7.18K	﹤0.01%	3944
2019 Q3	$18K	Buy	2,962 +1,582	+115%	+$9.87K	﹤0.01%	4040
2019 Q2	$9K	Buy	1,380 +770	+126%	+$5.43K	﹤0.01%	4451
2019 Q1	$4K	Buy	610 +200	+49%	+$1.32K	﹤0.01%	4807
2018 Q4	$2K	Buy	410 +145	+55%	+$755	﹤0.01%	4876
2018 Q3	$2K	Buy	+265	New	+$1.94K	﹤0.01%	4896

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Advisor Group's GNMK Position: Q4 2019 in Review

Advisor Group increased its GenMark Diagnostics, Inc (GNMK) stake by 44% in Q4 2019, buying an estimated $7.18K and bringing the position to 4,264 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #3944.

Advisor Group first reported a position in GNMK in Q3 2018 and has held it in 6 quarters since. 111 funds tracked by Wall St. Rank hold GNMK as of Q4 2019.

Advisor Group held 4,264 shares of GenMark Diagnostics, Inc worth $21K as of Q4 2019.
Advisor Group bought 1,302 GenMark Diagnostics, Inc shares in Q4 2019, an estimated $7.18K.
GenMark Diagnostics, Inc made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3944 holding.
Advisor Group first reported a position in GenMark Diagnostics, Inc in Q3 2018 and has held it in 6 quarters since.
111 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.